Promol Mechanism of Action

Pharmacology: Pharmacodynamics: Paracetamol is an analgesic and antipyretic. The therapeutic effects of paracetamol are thought to be related to inhibition of prostaglandin synthesis, as a result of inhibition of cyclo-oxygenase. There is some evidence that it is a more effective inhibitor of central as opposed to peripheral cyclo-oxygenase. Paracetamol only has weak anti-inflammatory properties. This may be explained by the concept that inflammatory tissues have higher levels of cellular peroxides than other tissues and that cellular peroxides prevent inhibition of cyclo-oxygenase by paracetamol.
Pharmacokinetics: Paracetamol is rapidly and almost completely absorbed from the gastrointestinal tract. The concentration in plasma reaches a peak in 30 to 90 minutes and the plasma half-life is 1-4 hours after therapeutic doses. Paracetamol is relatively uniformly distributed throughout most body fluids. Binding of the drug to plasma proteins is variable; 20 to 30% may be bound at the concentrations encountered during acute intoxication. Following therapeutic doses 90-100% of the drug may be recovered in the urine within the first day. However, practically no paracetamol is excreted unchanged and the bulk is excreted after hepatic conjugation.
Pharmacokinetics in Renal Impairment: An increase in the interval between doses of paracetamol has been recommended for adults with chronic renal failure. Haemodiolysis may result in reduced plasma levels of paracetamol and therefore supplementary doses of paracetamol may be necessary in order to maintain therapeutic blood levels.
Pharmacokinetics in Hepatic Impairment: In mild liver disease, there is no evidence that paracetamol is harmful when taken at recommended doses. However, in severe liver disease, the plasma paracetamol half-life is significantly prolonged.